Video: Targeting SARS-CoV-2 by Reaction Biology

Reaction Biology presented biochemical protease assays targeting COVID-19 viral proteins PLpro and Mpro involved in viral polyprotein processing. The company also demonstrated surface plasmon resonance assays designed to block viral entry by targeting interactions between the Spike protein receptor binding domain and host ACE2 protein for antiviral drug discovery.
Scientist.com
Published on
November 6, 2020

On November 5, 2020, Reaction Biology shared its recent efforts to support the drug discovery community in a live webinar.

The panelists from Reaction Biology’s team — Kayleigh McGovern-Gooch, Manager of the Non-Kinase Biochemical Group and Rebecca Eells, Associate Director of Biophysics — presented on biochemical protease assays they have in their COVID panel and viral proteins involved in viral polyprotein processing (PLpro and Mpro). They also discussed their SPR assays for targeting viral entry by testing molecules that can block the interaction between the viral Spike protein (specially looking at the receptor binding domain in this work) and the host protein ACE2.

Below is a recording of the entire webinar and Q&A session.

If you have questions for Reaction Biology, email them at requests@reactionbiology.com or access their profile page on Scientist.com .

Interested in hosting a webinar with Scientist.com? Contact us at marketing@scientist.com .

Abstract molecular cluster with three connected blue-green spheres on a white background.

Take the Next Step

1
2
3

Explore Suppliers

Browse trusted partners with relevant expertise

Review Capabilities

Compare services, experience, and past work

Start Your Project

Connect and begin collaborating

Written by
Scientist.com
Share this post

Read Further

Read Further